. 2021 Aug 26;132(5):933–941. doi: 10.1002/lary.29766

Table III.

SNOT‐22 Total/Domain Descriptive Statistics, and Convergent and Divergent Validity.

SNOT‐22 Domain	Time	Mean ± SD, Median	Pearson Correlations
SNOT‐22 Domain	Time	Mean ± SD, Median	RS VAS	TSS	SF‐36 PCS	SF‐36 MCS	EQ‐VAS	UPSIT	LMK	NPS
Nasal
Phase 2	BL	2.6 ± 0.86, 2.6	0.50^*	0.69^*	−0.45^*	−0.31^*	−0.45^*	−0.35^*	0.09	0.07
Phase 2	End of treatment	1.4 ± 1.04, 1.1	0.73^*	0.86^*	−0.36^*	−0.25	−0.40^*	−0.74^*	0.68^*	0.31^*
Phase 3	BL	3.1 ± 0.82, 3.1	0.48^*	0.67^*	−0.42^*	−0.26^*	−0.29^*	−0.28^*	0.25^*	0.16^*
Phase 3	Week 24	1.67 ± 1.11, 1.50	0.69^*	0.78^*	–	–	−0.45^*	−0.50^*	0.52^*	0.42^*
Ear/facial
Phase 2	BL	1.1 ± 1.04, 0.8	0.43^*	0.44^*	−0.36^*	−0.48^*	−0.38^*	−0.03	−0.24	−0.08
Phase 2	End of treatment	0.5 ± 0.86, 8.3	0.39^*	0.39^*	−0.46^*	−0.50^*	−0.37^*	−0.40^*	0.19	−0.02
Phase 3	BL	1.4 ± 1.15, 1.3	0.33^*	0.37^*	−0.39^*	−0.42^*	−0.29^*	−0.09^*	0.11^*	0.08^*
Phase 3	Week 24	0.69 ± 0.89, 0.25	0.49^*	0.48^*	–	–	−0.38^*	−0.29^*	0.27^*	0.23^*
Sleep
Phase 2	BL	1.8 ± 1.24, 1.8	0.24^*	0.47^*	−0.28^*	−0.17	−0.25	−0.09	−0.00	0.13
Phase 2	End of treatment	0.8 ± 1.01, 0.5	0.41^*	0.61^*	−0.50^*	−0.32^*	−0.45^*	−0.43^*	0.34^*	0.13
Phase 3	BL	2.3 ± 1.40, 2.3	0.35^*	0.38^*	−0.34^*	−0.34^*	−0.31^*	−0.13^*	0.14^*	0.17^*
Phase 3	Week 24	1.30 ± 1.20, 1.0	0.45^*	0.48^*	–	–	−0.43^*	−0.27^*	0.20^*	0.26^*
Function
Phase 2	BL	1.8 ± 1.29, 1.7	0.28^*	0.46^*	−0.55^*	−0.50^*	−0.44^*	−0.05	−0.17	−0.06
Phase 2	End of treatment	0.8 ± 1.03, 0.3	0.35^*	0.50^*	−0.56^*	−0.62^*	−0.42^*	−0.36^*	0.16	−0.03
Phase 3	BL	2.1 ± 1.39, 2.3	0.33^*	0.32^*	−0.39^*	−0.49^*	−0.36^*	−0.12^*	0.11^*	0.09^*
Phase 3	Week 24	1.19 ± 1.17, 1.0	0.45^*	0.46^*	–	–	−0.47^*	−0.27^*	0.20^*	0.23^*
Emotion
Phase 2	BL	1.1 ± 1.12, 0.7	0.35^*	0.41^*	−0.30^*	−0.60^*	−0.48^*	−0.10	−0.11	0.10
Phase 2	End of treatment	0.5 ± 0.84, 0.0	0.41^*	0.45^*	−0.20	−0.63^*	−0.22	−0.31^*	0.11	−0.03
Phase 3	BL	1.7 ± 1.36, 1.7	0.31^*	0.32^*	−0.28^*	−0.64^*	−0.37^*	−0.10^*	0.08^*	0.13^*
Phase 3	Week 24	0.9 ± 1.08, 0.33	0.47^*	0.46^*	–	–	−0.42^*	−0.26^*	0.20^*	0.24^*
Total score
Phase 2	BL	41.0 ± 18.92, 40.5	0.46^*	0.64^*	−0.49^*	−0.48^*	−0.49^*	−0.19	−0.08	0.04
Phase 2	End of treatment	20.5 ± 17.55, 17.0	0.64^*	0.78^*	−0.50^*	−0.49^*	−0.47^*	−0.64^*	0.51^*	0.16
Phase 3	BL	50.9 ± 20.67, 50.0	0.45^*	0.53^*	−0.45^*	−0.48^*	−0.39^*	−0.19^*	0.18^*	0.16^*
Phase 3	Week 24	27.62 ± 20.17, 23.0	0.65^*	0.69^*	–	–	−0.52^*	−0.42^*	0.39^*	0.37^*

Magnitudes of the correlations are evaluated as weak (r < 0.30), moderate (r = 0.30–0.49), or strong (r ≥ 0.50).

P < .05.

BL = baseline; EQ‐VAS = EuroQol‐Visual Analog Scale; LMK = Lund‐Mackay score; MCS = mental component summary; NPS = Nasal Polyps Score; PCS = physical component summary; RS VAS = rhinosinusitis Visual Analog Scale; SD = standard deviation; SF‐36 = 36‐Item Short‐Form Health Survey; SNOT‐22 = 22‐item Sinonasal Outcome Test; TSS = Total Symptom Score (of the symptoms e‐diary; computed as the sum of the weekly averages of nasal congestion/obstruction item, the average of the 2 anterior/posterior rhinorrhea items, and the loss of sense of smell item); UPSIT = University of Pennsylvania Smell Identification Test.